SRI International And Telik Announce Exclusive License For SRI To Develop Autoimmune And Inflammatory Disease Drug Candidate

... SRI International, an independent nonprofit research and development organization, and Telik, Inc. (Nasdaq: TELK) today announced that they have signed an exclusive license agreement under which SRI will conduct preclinical studies of a Telik drug candidate for the treatment of multiple sclerosis and other autoimmune and inflammatory diseases. [click link for full article] ...